Responding to an FDA 483 and a Warning Letter
A Form FDA 483 lists what the investigator observed; it is not FDA’s final decision on compliance. What happens next depends heavily on the firm’s response: FDA’s 2009 program and the current Investigations Operations Manual both tell firms that an adequate response within 15 business days may affect whether further action follows. A credible response answers each observation at the level of the system, proves what has been done, and commits only to what will be done. If a warning letter follows, it sets its own deadline, usually 15 working days, and it is closed only when FDA has verified the correction.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
What a 483 Is, and What It Is Not
Section 704(b) of the FD&C Act requires the investigator to give the firm a written report of objectionable conditions before leaving the premises; the Form FDA 483 is that report. Every 483 carries FDA’s preprinted statement that the items are inspectional observations and do not represent a final agency determination of compliance, and that the firm may discuss an objection or a corrective action during the inspection or submit it in writing. Device 483s add that the observations are not an exhaustive list, and that the firm is responsible for its own internal audits to find and correct all quality-system violations.
The IOM tells investigators to list only significant observations, rank them by significance, make each clear and specific, note when an observation repeats one from a prior inspection, and express it against its population — “two out of 50 records examined” — answering who, what, when, where, why, how much and how often. They are told not to quote regulations or standards on the form, not to cite deviations from guidance, and not to call a condition “violative”, because that is an agency decision made after review. A 483 can become public through FOIA requests, FDA postings and the trade press.
The Close-Out, Annotations and the Inspection Report
At close-out the firm may have each observation annotated with one of seven statuses: reported corrected, not verified; corrected and verified; promised to correct; promised to correct by a date; promised to correct within a time interval; under consideration; or left intentionally blank. Annotation must be offered on every medical device inspection; elsewhere it is at the program division’s discretion, and bioresearch-monitoring inspections are generally excluded. It is voluntary, and objections are not annotated. A condition corrected during the inspection stays on the 483.
The investigator’s Establishment Inspection Report records, for each observation, the supporting evidence and management’s response, including the time frames given and any disagreement or refusal to correct. It also records whether management was told about the 15-business-day response window. Corrective actions do not go on the 483 itself; they are reported in the inspection report. The close-out conversation is therefore already evidence: commit in the room only to what the firm will do.
Why the 15 Business Days Matter
In August 2009 FDA announced a program (74 FR 40211, starting 15 September 2009) under which it will generally allow 15 business days for a response to a 483 before deciding whether to issue a warning letter. A response received in time gets a detailed review, and any warning letter that follows acknowledges it and states whether the corrective actions appear adequate. FDA does not plan to address a later response in the warning letter routinely; it is evaluated together with the response to the letter. The 2026 IOM keeps the same window, measured from the end date of the inspection, which is the day the 483 is issued.
Two points from the same notice are easy to miss. Ongoing or promised corrective actions generally do not prevent a warning letter. And firms are expected to correct violations whether or not they respond in writing, and whether or not FDA reviews the response. For device establishments, section 704(h)(2) lets a firm make a timely request for nonbinding FDA feedback, within 45 days, on actions it proposes in response to a 483 that involve a public health priority, systemic or major actions, or emerging safety issues.
What FDA Weighs in a Response
FDA’s Regulatory Procedures Manual (Chapter 4, Revision 12, July 2024) lists what a program office considers when a firm is correcting or has promised to: its compliance history; whether the firm knew of the violation and failed to correct it; the risk of the product; the overall adequacy of the corrective action, including whether it covers the specific violations, related violations, and related products or facilities, and has provisions for monitoring and review to ensure effectiveness; whether documentation was provided for an informed evaluation; whether the timeframe is appropriate and progress is real; and whether the correction ensures sustained compliance. If FDA concludes that completed corrections are adequate, it generally does not issue a warning letter, and may send a response letter recording that it is relying on the firm’s actions.
SPEQ synthesis: answer each observation in the same order and with the same structure. Restate the observation verbatim; describe the investigation, including how far beyond the investigator’s sample the problem extends; state the root cause; describe the correction of the specific instances and the systemic corrective and preventive action; attach the evidence; give owners and dates; and say how effectiveness will be checked. Where the 483 says “2 of 50 records”, the response must account for the other 48 and every other place the same process runs. Report progress on open commitments until they are complete.
Warning Letters
A warning letter is issued only for violations of regulatory significance — violations that may lead to enforcement action if not promptly and adequately corrected. It is informal and advisory, and FDA does not regard it as final agency action. It is also not a precondition: FDA may take enforcement action without one, for example where violations are repeated, intentional or present a reasonable possibility of injury or death. Under the RPM, the program office should submit a warning letter recommendation for review within 15 working days of completing the inspection, and an issued warning letter means the inspection is classified Official Action Indicated.
The letter usually asks for a written response within 15 working days of receipt, covering each step taken or to be taken to correct the violations and prevent their recurrence, the time to complete it, the reasons anything is not complete within the response time, and the documentation that shows correction. It usually invites the firm to explain, with evidence, if it believes it is not in violation. Drug letters citing CGMP state that the violations may be cause for FDA to withhold export certificates and, where appropriate, approval of new applications or supplements naming the firm; device letters state that certificates to foreign governments may not be granted and, where quality-system violations relate to Class III premarket approval applications, that those devices will not be approved until the violations are corrected.
Close-Out and What Comes After
A warning letter close-out letter is not issued on promises. The corrections must actually have been made and verified by FDA — usually by a follow-up inspection, or by other verified information — and the verification must not reveal other significant violations. Close-out letters apply to warning letters issued on or after 1 September 2009, and FDA posts a notice when one is issued. The warning letter itself stays on FDA’s website unless FDA rescinds or amends it, although the firm can ask FDA to post its response alongside.
A close-out letter does not end the obligation. If a later inspection finds that the corrections were not adequate or not sustained, FDA treats those violations as serious and may act without further notice. The response is therefore a commitment the next inspection will test, and the CAPA records behind it must hold up as well as the letter does.
FREQUENTLY ASKED
Is a response to a Form FDA 483 required?
No — it is voluntary. But FDA’s 2009 program and the current IOM both say that an adequate response within 15 business days may affect FDA’s decision on further action, and FDA expects firms to correct violations whether or not they respond.
Does a good 483 response prevent a warning letter?
It can, but promises alone generally do not. FDA’s Regulatory Procedures Manual says ongoing or promised corrective actions generally do not preclude a warning letter; if FDA concludes that completed corrections are adequate and the violations corrected, it generally does not issue one.
Can an observation be removed from a 483?
Errors found before the investigator leaves are corrected on the form, and if an observation is removed after discussion with management the form says so. An objectionable condition that was corrected during the inspection stays on the 483; the correction is reported in the inspection report instead.
How long does a firm have to answer a warning letter?
The letter states the period. FDA’s Regulatory Procedures Manual says it is usually 15 working days from receipt, and the response should explain any corrective action that cannot be completed within that time.
When is a warning letter closed out?
Only after FDA has verified that the corrections were made — usually by a follow-up inspection — and found no other significant violations. The close-out letter does not remove the warning letter from FDA’s website, and later problems with the same corrections are treated as serious.
The inspection-readiness playbook for this topic
PUT THIS PLAYBOOK TO WORK
- HOW-TO GUIDEHow to Respond to an FDA 483 →Write a Form FDA 483 response FDA can rely on — inside the 15 business days.
- TEMPLATEFDA 483 and Warning Letter Response →
- HOW-TO GUIDEHow to Respond to an FDA Warning Letter →Answer a warning letter completely, within its deadline, and work toward a close-out letter.
- TEMPLATEFDA 483 and Warning Letter Response →
A free account keeps what you save, remembers where you are across devices, and can send you the weekly regulatory briefing. Create a free account